Stempoint Capital LP Boosts Stock Holdings in SAB Biotherapeutics, Inc. $SABS

Stempoint Capital LP grew its holdings in SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 155.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 375,000 shares of the company’s stock after purchasing an additional 228,442 shares during the quarter. Stempoint Capital LP’s holdings in SAB Biotherapeutics were worth $1,436,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. PNC Financial Services Group Inc. bought a new position in shares of SAB Biotherapeutics during the first quarter valued at approximately $29,000. ADAR1 Capital Management LLC purchased a new position in SAB Biotherapeutics during the third quarter valued at approximately $30,000. Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics in the third quarter worth approximately $32,000. State of Wyoming bought a new position in SAB Biotherapeutics in the fourth quarter worth approximately $34,000. Finally, Virtu Financial LLC purchased a new stake in SAB Biotherapeutics during the third quarter worth $40,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Price Performance

NASDAQ SABS opened at $3.48 on Thursday. The firm’s fifty day simple moving average is $3.68 and its two-hundred day simple moving average is $3.84. The firm has a market capitalization of $266.08 million, a P/E ratio of -1.65 and a beta of 0.52. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics, Inc. has a 12-month low of $1.85 and a 12-month high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Analysts forecast that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SABS. Citigroup initiated coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 target price on the stock. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Leerink Partners raised their price objective on SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Chardan Capital boosted their target price on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SAB Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.